FILINGS
| GLAXF 0001131399 | |||
|---|---|---|---|
| Filing Date | Form Type | Description | Document |
| 2025-08-04 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-08-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-08-01 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-07-31 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-07-30 | 6-K | 2ND QUARTER RESULTS | View Document |
| 2025-07-30 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-07-29 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-07-28 | 6-K | GSK ENTERS HENGRUI PHARMA COLLABORATION AGREEMENTS | View Document |
| 2025-07-28 | 6-K | PRIMARY DOCUMENT | View Document |
| 2025-07-25 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-07-24 | 6-K | BLENREP APPROVED IN THE EU FOR MULTIPLE MYELOMA | View Document |
| 2025-07-24 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-07-23 | 6-K | US FDA REVIEW EXTENDED FOR BLENREP | View Document |
| 2025-07-23 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-07-22 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-07-21 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-07-18 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-07-18 | 6-K | BLENREP US ODAC OUTCOME | View Document |
| 2025-07-18 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-07-17 | 6-K | GSKS SHINGRIX FULLY LIQUID FDA APPROVAL | View Document |
| 2025-07-17 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-07-16 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-07-15 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-07-15 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-07-14 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-07-14 | 6-K | GSK SUBMITS AREXVY FOR ADULTS 18-49 AIR TO FDA | View Document |
| 2025-07-14 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-07-11 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-07-10 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-07-09 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-07-08 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-07-07 | 6-K | GSK COMPLETES ACQUISITION OF EFIMOSFERMIN FOR SLD | View Document |
| 2025-07-07 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-07-07 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-07-03 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-07-02 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-07-01 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-07-01 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-30 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-27 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-26 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-25 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-24 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-06-24 | 6-K | DIRECTOR DECLARATION | View Document |
| 2025-06-24 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-23 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-06-23 | 6-K | LINERIXIBAT FILE ACCEPTED BY EMA | View Document |
| 2025-06-23 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-20 | 6-K | AREXVY FILED IN JAPAN FOR 18-49 AT INCREASED RISK | View Document |
| 2025-06-20 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-20 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-18 | 11-K | ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE | View Document |
| 2025-06-18 | 11-K | ANNUAL REPORT OF EMPLOYEE STOCK PURCHASE PLANS | View Document |
| 2025-06-18 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-17 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-16 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-06-13 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-13 | 6-K | GSK SUBMITS AREXVY FOR ADULTS 18+ WITH EMA | View Document |
| 2025-06-12 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-06-12 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-11 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-06-11 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-10 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-09 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-06 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-05 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-04 | 6-K | GSK - SECOND TRANCHE OF SHARE BUYBACK PROGRAMME | View Document |
| 2025-06-04 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-03 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-06-02 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-06-02 | 6-K | TOTAL VOTING RIGHTS | View Document |
| 2025-06-02 | 6-K | LINERIXIBAT FILE ACCEPTED FOR REVIEW BY US FDA | View Document |
| 2025-06-02 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-30 | SD | SPECIALIZED DISCLOSURE REPORT | View Document |
| 2025-05-30 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-29 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-28 | 6-K | GSK STOPS PHASE 3 TRIAL ON CUTIS FOR EFFICACY | View Document |
| 2025-05-28 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-27 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-23 | 6-K | POSITIVE CHMP OPINION ON BLENREP IN EU | View Document |
| 2025-05-23 | 6-K | FDA APPROVES NUCALA COPD INDICATION | View Document |
| 2025-05-23 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-22 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-21 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-20 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-05-20 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-19 | 6-K | BLENREP FOR 2L+ MULTIPLE MYELOMA APPROVED IN JAPAN | View Document |
| 2025-05-19 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-16 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-15 | 25-NSE | View Document | |
| 2025-05-15 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-14 | 6-K | GSK TO ACQUIRE EFIMOSFERMIN | View Document |
| 2025-05-14 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-13 | 6-K | DIRECTOR/PDMR SHAREHOLDING | View Document |
| 2025-05-13 | 6-K | UPDATE ON BELRESTOTUG DEVELOPMENT PROGRAMME | View Document |
| 2025-05-13 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-12 | 6-K | BLOCK LISTING INTERIM REVIEW | View Document |
| 2025-05-12 | 6-K | TRANSACTION IN OWN SHARES | View Document |
| 2025-05-09 | 6-K | TRANSACTION IN OWN SHARES | View Document |
Search company filings and access detailed reports including 10-K, 10-Q, 8-K, and other critical filings. Stay informed on corporate disclosures, regulatory filings, and updates with our easy-to-use EDGAR API filings search tool.
